Publications by authors named "Chris M Stainsby"
Article Synopsis
- - HLA-B*57:01 screening was introduced in 2008 to minimize the risk of hypersensitivity reactions in patients starting abacavir, with a study analyzing its uptake and effectiveness in the US.
- - From 1999 to 2016, the percentage of patients screened for HLA-B*57:01 prior to starting abacavir rose significantly from 43% in 2009 to 84% in 2015, while hypersensitivity reactions dropped from 1.3% to 0.2% during the same timeframe.
- - Despite the increased screening rates, many patients still underwent abacavir treatment without screening, indicating areas for improvement in preventing potential hypersensitivity reactions.
Introduction: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus treatment guidelines in 2008. Company meta-analyses of trials pre-HLA-B*5701 screening reported HSR rates of 4-8%.
View Article and Find Full Text PDF